Journavx and Lyrica Safety in Ankle Fracture Patient with CKD
Journavx (suzetrigine) can be used without dose adjustment in CKD patients with eGFR >15 mL/min, while Lyrica (pregabalin) requires significant dose reduction based on creatinine clearance and carries increased risk of adverse effects including falls and fractures in this population.
Journavx (Suzetrigine) in CKD
According to the FDA label, **Journavx has not been studied in patients with eGFR <15 mL/min and should be avoided in this population** 1. However, for patients with eGFR >15 mL/min, the recommended dosage is the same as those with normal kidney function 1. This is a significant advantage over many other analgesics in CKD patients.
Key Points for Journavx:
- No dose adjustment needed if eGFR >15 mL/min
- Avoid if eGFR <15 mL/min
- Not primarily renally cleared (undergoes minimal metabolism <2%) 1
- Monitor for common side effects: itching, muscle spasms, increased CPK, rash 1
Lyrica (Pregabalin) in CKD
Pregabalin requires substantial dose reduction in CKD and carries documented risks that are particularly concerning for a patient with an ankle fracture. The drug is primarily renally cleared, with clearance directly proportional to creatinine clearance 2, 3.
Dose Adjustments Required:
Based on pharmacokinetic studies 2:
- CrCl 30-60 mL/min: Reduce daily dose by 50%
- CrCl 15-29 mL/min: Reduce by an additional 50% (75% total reduction)
- CrCl <15 mL/min: Further reduction required; supplemental doses needed post-hemodialysis
Critical Safety Concerns:
Recent evidence demonstrates pregabalin significantly increases fracture risk 4. A 2025 case-case-time-control study showed:
- OR 1.35 (95% CI 1.28-1.43) for fracture risk with pregabalin
- Risk remained consistent across sensitivity analyses
- Effect particularly pronounced in patients ≥65 years
Additionally, patients with CrCl <60 mL/min receiving inappropriately high pregabalin doses experienced significantly increased falls (P=0.029) 5. This is especially problematic for an ankle fracture patient who already has compromised mobility.
Toxicity Risk in CKD:
Pregabalin toxicity manifests as 6, 7:
- Myoclonus (both positive and negative)
- Progressive weakness and lethargy
- Gait disturbance
- Altered mentation
- Diplopia and confusion
These neurological effects are amplified in kidney dysfunction due to reduced clearance and accumulation 5, 2.
Clinical Decision Framework
Check the following before prescribing:
Calculate eGFR/CrCl accurately - Use validated equations; consider cystatin C if precision needed 8
For Journavx:
- If eGFR >15 mL/min → Standard dosing (100 mg loading, then 50 mg q12h)
- If eGFR <15 mL/min → Avoid use
For Pregabalin:
- Calculate exact CrCl
- Apply appropriate dose reduction (see above)
- Consider avoiding entirely given fracture risk and fall risk in CKD
- If used, start at lowest dose and titrate carefully 9
Monitoring Requirements:
Per KDIGO 2024 guidelines 8:
- Monitor eGFR and electrolytes regularly
- Assess for adverse effects at each visit
- Perform medication reconciliation at transitions of care
- Educate patient on reportable symptoms
Common Pitfalls to Avoid
Using standard pregabalin doses in CKD - Studies show 34% of patients with CrCl <60 mL/min receive inappropriately high gabapentinoid doses 5
Ignoring fall/fracture risk - The combination of ankle fracture + pregabalin + CKD creates compounded fall risk 4, 5
Failing to adjust for acute illness - Consider temporary discontinuation during intercurrent illness that could worsen kidney function 8, 10
Not monitoring therapeutic response - CKD alters pharmacokinetics unpredictably; close follow-up essential 11
Recommendation
For acute pain management in an ankle fracture patient with CKD, Journavx is the safer choice if eGFR >15 mL/min, as it requires no dose adjustment and lacks the documented fracture/fall risk associated with pregabalin. If pregabalin must be used, mandatory dose reduction based on CrCl is required, with heightened vigilance for neurological adverse effects and fall risk 8, 4, 5, 2.